Cytophage Technologies Ltd.CYTO.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · cytophage.com

Cytophage Technologies Ltd. is a Canadian biotechnology company specializing in bacteriophage research, product development, and commercialization, headquartered in Winnipeg, Manitoba. The company develops precision phage therapeutics to combat antibiotic-resistant bacterial infections across human health, animal health, and food security applications. Cytophage has received Canadian regulatory approvals and successfully treated patients with its bacteriophage therapies targeting difficult-to-treat prosthetic joint infections.

Key ratios

ROA

-60.1%TTM

2024 -62.3%2023 -69.0%

ROE

-171.1%TTM

2024 -475.9%2023 -242.4%

Recent news

Cytophage Announces Filings Under the BIA 2026-05-22 · Stockhouse Cytophage Announces Departure of Chief Operating Officer 2026-04-14 · TheNewsWire Cytophage Announces Formation of Special Committee of Independent Directors to Evaluate Strategic Alternatives 2026-03-06 · TheNewsWire Cytophage Announces Operational Restructuring 2026-02-19 · TheNewsWire

Track CYTO.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer